Next-Generation Bispecific Nanobody Targeting KLKB1 and VEGF for Vascular Disorders

VHH-P534 is a humanized nanobody-based bispecific fusion construct currently undergoing biological testing, developed for the treatment of vascular disorders. This innovative therapeutic candidate is designed to target two well-validated molecules: kallikrein B1 (KLKB1) and vascular endothelial growth factors (VEGF), both integral to the regulation of vascular function and pathology. By simultaneously engaging KLKB1 and VEGF, VHH-P534 is positioned to offer a dual-modulatory approach for patients with vascular disorders, addressing complex disease mechanisms and potentially overcoming limitations of traditional single-target therapies.

Licensing Opportunity

VHH-P534 is actively available for out-licensing and partnership opportunities. We welcome collaboration with pharmaceutical and biotechnology partners seeking innovative solutions for vascular disorder therapies.

Development Phase

Modality

VHH-P534 employs a bispecific fusion protein modality that combines VEGF-binding portions derived from the extracellular domains of human VEGF receptors 1 and 2 with a single-domain nanobody targeting KLKB1, connected via a flexible G4S linker. As a nanobody-based construct, it leverages the inherent advantages of single-domain antibodies, including small molecular size, conformational stability, and robust tissue penetration. These features are particularly beneficial for vascular disorders, where deep and efficient tissue targeting is critical for therapeutic efficacy. The modular design of VHH-P534 enables high specificity for both targets while maintaining pharmacological versatility and manufacturing feasibility.

Target

KLKB1 and VEGF are two critical molecular targets involved in vascular biology. KLKB1 is a serine protease crucial for the kallikrein-kinin system, influencing vascular permeability, inflammation, and coagulation. VEGF is a key regulator of angiogenesis, promoting endothelial cell proliferation, migration, and vessel permeability, and is predominantly expressed in vascular endothelial tissues under both physiological and pathological conditions. Both KLKB1 and VEGF play significant roles in the pathogenesis of vascular disorders, including edema, angiogenesis-related tissue remodeling, and abnormal thrombosis. Strategic dual targeting of KLKB1 and VEGF by VHH-P534 addresses multiple disease pathways, offering potential for a more comprehensive disease-modifying effect in vascular disorders therapy. By simultaneously modulating KLKB1 and VEGF activities, this bispecific nanobody construct provides a highly attractive asset for therapeutic development in complex vascular conditions.

Mechanism of Action

VHH-P534 acts by dual inhibition of KLKB1 and VEGF, providing a mechanistic basis for its potential in vascular disorders. By binding to KLKB1, it interferes with the kallikrein-kinin system, modulating key pathways that govern vascular permeability and inflammatory cascades. Concurrently, the anti-VEGF component of VHH-P534 functions as an angiogenesis inhibitor, disrupting VEGF-mediated endothelial cell signaling and pathological neovascularization. Collectively, these mechanisms converge to suppress abnormal vascular remodeling and leakage, hallmarks of many vascular disorders. The single-domain antibody platform underlying VHH-P534 is highly adaptable, offering avenues for multi-valent formats; this provides further opportunities for expansion into antibody-drug conjugates or additional bi-specific and multi-specific constructs.

Vascular Disorders

Vascular disorders encompass a wide spectrum of conditions affecting blood vessel function, integrity, and structure—such as chronic venous insufficiency, hereditary angioedema, diabetic microangiopathies, and various forms of edema and thrombosis. These disorders contribute significantly to global disease burden, impacting quality of life and increasing mortality risk. Current treatment paradigms typically involve anticoagulants, anti-inflammatory agents, and surgical interventions, as well as targeted therapies such as angiogenesis inhibitors for specific indications. However, progress is limited by suboptimal efficacy, risk of adverse effects, and incomplete targeting of the underlying multifactorial disease mechanisms. There remains a considerable unmet need for therapies capable of addressing both aberrant angiogenic activity and dysregulated protease signaling. VHH-P534 offers a promising therapeutic solution for vascular disorders by simultaneously targeting VEGF- and KLKB1-mediated pathways, potentially delivering superior disease control and reducing treatment resistance compared to single-targeted agents. Its unique bispecific design targets fundamental aspects of vascular pathology, opening new avenues for effective management of these complex diseases.